Janus激酶抑制剂对因COVID-19住院成人的影响:随机临床试验的系统评价与个体参与者数据Meta分析
该个体参与者数据Meta分析纳入12项RCT(共12902例因COVID-19住院的成人),比较JAK抑制剂与无JAK抑制剂(标准治疗±安慰剂)。JAK抑制剂组28天死亡755/6465(11.7%),对照组805/6108(13.2%),aOR 0.67(95%CI 0.55-0.82),每1000例减少39例死亡(95%CI 减少55至减少21),证据确定性高。JAK抑制剂减少新需要有创机械通气或其他呼吸支持,缩短住院约1天,并减少3-4级不良事件和严重不良事件(每1000例减少14例,95%CI 减少24至减少4),特殊关注不良事件两组相似。未发现通气状态、JAK抑制剂类型、合并症、症状出现后治疗时机、CRP浓度或联用地塞米松/托珠单抗对28天死亡率有可信的亚组效应;年龄有中等可信的效应修饰,年轻参与者相对效应更大但绝对效应相似。
要点
- 因COVID-19住院的成人使用JAK抑制剂较无JAK抑制剂降低28天死亡率:11.7%(755/6465)vs 13.2%(805/6108),aOR 0.67(95%CI 0.55-0.82),每1000例减少39例死亡(95%CI 减少55至减少21),证据确定性高。
- JAK抑制剂减少新需要有创机械通气或其他呼吸支持的需求,并使出院加快约1天。
- JAK抑制剂组3-4级不良事件和严重不良事件更少(每1000例减少14例,95%CI 减少24至减少4),特殊关注不良事件两组相似。
- 28天死亡率的效应在各呼吸支持水平均一致,不依赖是否联用地塞米松或托珠单抗;未发现通气状态、JAK抑制剂类型、合并症、治疗时机、CRP浓度的可信亚组效应。
- 年龄有中等可信的效应修饰:年轻参与者相对治疗效应更大,但因老年参与者基线风险更高,绝对治疗效应相似。
适用人群与场景
- 年龄≥16岁、因COVID-19住院的成人,来自12项随机对照试验的个体参与者数据。
- 纳入试验为将因COVID-19住院成人随机分配至JAK抑制剂(任何类型)或无JAK抑制剂(即接受所在中心标准治疗,联用或不联用安慰剂)的RCT。
处置流程与药物剂量
- 7项试验评估巴瑞替尼,3项评估托法替布,2项评估芦可替尼;具体剂量、途径、频次及疗程原文未报告。
研究设计与关键结果
- 系统评价与个体参与者数据Meta分析:检索至2024年11月28日,鉴定16项合格RCT,获得12项试验的个体参与者数据,共12902例成人,住院时间在2020年5月至2022年3月之间,占所有合格试验13423例参与者的96.1%。
- 主要终点28天全因死亡率:JAK抑制剂组755/6465(11.7%)vs 无JAK抑制剂组805/6108(13.2%),校正年龄和呼吸支持后aOR 0.67(95%CI 0.55-0.82),证据确定性高;每1000例减少39例死亡(95%CI 减少55至减少21)。
- JAK抑制剂减少新需要有创机械通气或其他呼吸支持的需求,并使出院加快约1天。
- 3-4级不良事件和严重不良事件:JAK抑制剂组每1000例减少14例(95%CI 减少24至减少4),证据确定性中等;特殊关注不良事件两组发生率相似。
- 未发现通气状态、JAK抑制剂类型、合并症、症状出现后治疗开始时机、C反应蛋白浓度或联用地塞米松/托珠单抗对28天死亡率有可信的亚组效应。
- 年龄有中等可信的效应修饰:年轻参与者相对治疗效应更大,但因老年参与者基线风险更高,绝对治疗效应相似。
证据类型、等级与局限
- 证据类型:随机对照试验的系统评价与个体参与者数据Meta分析,采用GRADE方法评定证据确定性;主要终点28天死亡率为高确定性证据,3-4级不良事件和严重不良事件为中等确定性证据。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:JAK抑制剂降低因COVID-19住院成人的死亡率,且在各呼吸支持水平均一致,不依赖地塞米松或托珠单抗,并可能减少严重和重度不良事件。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Evidence from randomised clinical trials (RCTs) of Janus kinase (JAK) inhibitors-compared with usual care or placebo-in adults treated in hospital for COVID-19 is conflicting. We aimed to evaluate the benefits and harms of JAK inhibitors compared with placebo or usual care and whether treatment effects differed between prespecified participant subgroups.
METHODS: For this systematic review and individual participant data meta-analysis (IPDMA), we searched Medline via Ovid, Embase via Elsevier, the Cochrane Central Register of Controlled Trials, the Cochrane COVID-19 Study Register, and the COVID-19 L·OVE Platform, including backward and forward citation searching (last search Nov 28, 2024), for RCTs (unpublished or published in any format and any language) that randomly assigned adults (aged ≥16 years) admitted to a hospital due to COVID-19 to receive either a JAK inhibitor (any type) or no JAK inhibitor (ie, received site-specific standard of care with or without placebo), and requested individual participant data (IPD) from the original trial teams. The primary outcome was all-cause mortality at day 28 after random assignment. We used two-stage meta-analyses adjusting for age and respiratory support, and pooled estimates using random-effects models. The assessment of individual-level effect modifiers was based solely on within-trial information and continuous modifiers were investigated as both linear and non-linear interactions. We used the Instrument for Assessing the Credibility of Effect Modification Analyses to appraise the subgroup analyses and the Grading of Recommendations Assessment, Development, and Evaluation approach to adjudicate the certainty of evidence. Grade 3 or 4 adverse events and serious adverse events by day 28, and adverse events of special interest within 28 days, were assessed among secondary outcomes. This study was registered with PROSPERO (CRD42023431817).
FINDINGS: We identified 16 eligible trials. IPD were obtained from 12 trials, corresponding to 12 902 adults admitted to hospital between May, 2020, and March, 2022. These trials represented 12 902 [96·1%] of 13 423 participants from all eligible trials worldwide. Seven trials evaluated baricitinib, three evaluated tofacitinib, and two evaluated ruxolitinib. Overall, 755 (11·7%) of 6465 participants in the JAK inhibitor group died by day 28 compared with 805 (13·2%) of 6108 participants in the no JAK inhibitor group (adjusted odds ratio [aOR] 0·67 [95% CI 0·55-0·82]; high-certainty evidence; 39 fewer per 1000 [95% CI 55 fewer to 21 fewer]). JAK inhibitors decreased the need for new mechanical ventilation or other respiratory support and allowed for faster discharge from hospital by about 1 day. We observed fewer grade 3 and 4 adverse events and serious adverse events in the JAK inhibitor group (14 fewer per 1000 [95% CI 24 fewer to 4 fewer]; moderate-certainty evidence). The rates of adverse events of special interest were similar across both groups. No credible subgroup effect on mortality at day 28 was found for ventilation status, type of JAK inhibitor, presence of comorbidities, timing of treatment initiation after symptom onset, C-reactive protein concentration, or concomitant use of dexamethasone or tocilizumab. We found a moderately credible effect modification by age, with younger participants showing larger relative treatment effects than older participants, but similar absolute treatment effects due to higher baseline risk for older participants.
INTERPRETATION: This IPDMA of RCTs in adults admitted to hospital due to COVID-19 found that JAK inhibitors reduced mortality across all levels of respiratory support, independent of dexamethasone or tocilizumab, and probably decreased serious and severe adverse events compared with no JAK inhibitors.
FUNDING: This project has received funding from the EU's Horizon 2020 research and innovation programme under grant agreement number 101015736.
参考来源
- Amstutz A, Schandelmaier S, Ewald H, et al. Effects of Janus kinase inhibitors in adults admitted to hospital due to COVID-19: a systematic review and individual participant data meta-analysis of randomised clinical trials. Lancet Respir Med. 2025. PMID: 40378861. doi:10.1016/S2213-2600(25)00055-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。